Avant, Paul Capital Partners deal

Paul Capital's Paul Royalty Fund II plans to pay up to $61 million to purchase a portion of the royalty that AVAN receives from GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) on the pharma company'...